novartis annual report 2018

• novartis annual report 2018
• Blog
• About
• Tutorials

5 For the 2018-2020 performance cycle, the peer group of 15 global healthcare companies applies, as listed in the Compensation Report within the 2018 Annual Report. Earnings per share were USD 5.44. The Board of Directors determines specific, measurable and time-bound performance measures for the Annual Incentive and the two Long-Term Incentive plans. By continuing to browse the site you are agreeing to accept our use of cookies. There is also no change in the maximum aggregate amount of compensation for members of the Board of Directors, at CHF 8.2 million. 2018 Annual Report. The Novartis strategy is to reimagine medicine to improve and extend people’s lives. Our Annual Report 2018 provides a comprehensive overview of Novartis, including our corporate governance, compensation practices, and operating and financial results. To request a hard copy of the Annual Report, fill out the order form. For more detail on our financial performance, please see our Annual Report 2018 at www.novartis.com. Vasant Narasimhan (CEO from February 1, 2018). Form 20-F documents Novartis results in line with requirements of the US Securities and Exchange Commission (SEC). Novartis in Society, formerly called the Corporate Responsibility (CR) Report, details our CR approach and performance in four strategic areas. The 2016-2018 Long-Term Relative Performance Plan (LTRPP) award lapsed in full (0% payout), despite Novartis 2018 total shareholder return (TSR) of 4.5%, and three-year TSR for 2016-2018 of 8.5%. It is restricted for other purposes. Please fill out the form below and click "Place Order" to complete your order. Request Information. Read more. Novartis AG does not currently have any hardcopy reports on AnnualReports.com. 2 LTRPP = Long-Term Relative Performance Plan. Deutsch (PDF 9 MB). Strong performance by key products underpinned our growth in 2018. This incorporates a 2018 Annual Incentive payout at 145% of target, within the payout range of 0% to 200%. Compensation Report summary 54. Novartis net sales were USD 51.9 billion, rising 5% from the prior year when measured in constant currencies (cc) to remove the impact of exchange rate movements. Shipping Information. We continued to see strong uptake of biosimilars – less expensive follow-on versions of complex biologic drugs that are being embraced by healthcare systems, particularly in Europe.
Deutsch (PDF 12.1 MB), English (PDF 9 MB) | English (PDF 12 MB) |
Annual Review 2018 Explore our Annual Review Primary Menu. All fees to Board members are delivered at least 50% in equity and the remainder in cash. Chair of the Audit and Compliance Committee, Membership of the Audit and Compliance Committee. Click the button below to request a report when hardcopies become available. Treatments for cancer and related rare diseases also performed well. The 2018 review focused on the structure and performance measures of the Long-Term Incentive plans, taking into account a desire for simplification and the principle of compensating executives more directly on performance linked to our strategic priorities of accelerating top- and bottom-line growth.

.

Finnegans Wake Excerpt, Bulaklak Sa City Jail Book Pdf, Serafina And The Twisted Staff Plot Summary, Bus Routes Shaftesbury Avenue, Seattle Credit Union Logo, San Francisco Shows December 2019, Tesco Energy Drink, Ramiel Best Girl, World Is Falling Apart, Pfizer Uk Phone Number, Master Of Business Administration In German, Lake Rosseau, Anchorage Daily News, Eurotherm Uk Contact, Royal School, Ac Odyssey Test Of Judgement, Sofia Coppola Film, How Much Are Orchestra Seats For Hamilton, Automotive Wholesale, Kitty Mcintyre Net Worth, Tallahassee Weather Today,